AnaConDa e-learning released to meet increased inquiries related to COVID-19

As a response to an increased amount of inquiries, Sedana Medical has decided to release an e-learning to educate healthcare professionals in the practical use of the AnaConDa.

The extraordinary situation with the spread of COVID-19, has led to an increased amount of inquiries to Sedana Medical from intensive care units around the world for information about the use of the AnaConDa.

Travel restrictions and hospitals closed for visitors have made it difficult for Sedana Medical personal to meet and educate healthcare professionals in the use of the AnaConDa. To be able to support in best possible way Sedana Medical has decided to release their English beta-version of an AnaConDa e-learning. The aim of the e-learning is to help healthcare professionals understand the practical aspects of using the AnaConDa and how to do the setup.

To get access to the AnaConDa e-learning, please visit the Sedana Medical homepage, https://www.sedanamedical.com/?page_id=15818

For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
Mobile: +46 70 675 33 30
E-mail: christer.ahlberg@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

About Sedana Medical

Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhaled sedation in intensive care units with the pharmaceutical IsoConDa^® (isoflurane).

Sedana Medical has direct sales in Benelux, France, Nordics, Germany, Spain and Great Britain as well as external distributors in the rest of Europe, Australia, Japan, Canada, Mexico and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.